Paul Toren
Chercheur universitaire clinicien
Axe Oncologie
Dernières nouvelles
Voir toutPublications
Voir tout-
article Suartz CV, Lepine HL, Matalani CFA, Parente MPEA, Moura DS, Zollinger LBC, Lopes RI, Júnior JB, Cordeiro MD, Reis LO, Chun JTY, Motta JM, Nahas WC, Toren P, Ribeiro-Filho LA
The efficacy and safety of tranexamic acid use during radical cystectomy: A systematic review and meta-analysis
Can Urol Assoc J 2025.
-
article Suartz CV, de Lima RD, de Almeida LS, Liebl B, Lopes RI, Branquinho Reis GB, Henry Sant'Anna PV, Faris de Campos VD, Mota JM, Lima Aguiar Melão BV, Nahas WC, Shahrour W, Shabana W, Ribeiro-Filho LA, Toren P, Fradet V
Neoadjuvant Immunotherapy in Bladder Cancer: Ushering in a New Era of Treatment-A Systematic Review of Current Evidence
Eur Urol Open Sci 79 2025.
-
article Suartz CV, Roy ML, Toren P
The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Metastatic Castrate-Sensitive Prostate Cancer Patients Treated with Abiraterone Acetate
Soc Int Urol J 5 (4), 2024.
Projets
- Targeting sex steroids to improve the response to bladder cancer immunotherapy, du 2021-10-01 au 2026-09-30
- Repurposing bicalutamide to improve the response to immune checkpoint inhibition for treatment of advanced urothelial carcinoma, du 2022-08-01 au 2026-07-31
- Étude des interactions endo-immunitaires pour améliorer le traitement des carcinomes urothéliaux, du 2024-07-01 au 2028-06-30
- Circulating basophils and eosinophils as novel biomarkers for non-muscle invasive cancer bladder cancer, du 2024-09-01 au 2026-08-31
- Gut microbiota biomarkers to personalize treatment of bladder cancer, du 2024-12-01 au 2027-04-30
- Repurposing 5-alpha reductase inhibitors to improve outcomes for bladder cancer patients, du 2025-10-01 au 2030-09-30
- Exploiter les interactions endocriniennes-immunes pour améliorer le traitement des cancers urologiques, du 2022-07-01 au 2024-06-30